<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0300-9041</journal-id>
<journal-title><![CDATA[Ginecología y obstetricia de México]]></journal-title>
<abbrev-journal-title><![CDATA[Ginecol. obstet. Méx.]]></abbrev-journal-title>
<issn>0300-9041</issn>
<publisher>
<publisher-name><![CDATA[Federación Mexicana de Colegios de Obstetricia y Ginecología A.C.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0300-90412021001100006</article-id>
<article-id pub-id-type="doi">10.24245/gom.v89i11.5207</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Carcinosarcoma de ovario en paciente perimenopáusica]]></article-title>
<article-title xml:lang="en"><![CDATA[Ovarian carcinosarcoma in a perimenopausal woman]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rodríguez Sánchez-Reyman]]></surname>
<given-names><![CDATA[Julia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Luque-González]]></surname>
<given-names><![CDATA[Pablo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Gutiérrez-Domingo]]></surname>
<given-names><![CDATA[Álvaro]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rodríguez-Jiménez]]></surname>
<given-names><![CDATA[Inmaculada]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Pantoja-Garrido]]></surname>
<given-names><![CDATA[Manuel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Universitario Virgen Macarena  ]]></institution>
<addr-line><![CDATA[Sevilla ]]></addr-line>
<country>España</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Hospital Universitario Virgen Macarena  ]]></institution>
<addr-line><![CDATA[Sevilla ]]></addr-line>
<country>España</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>00</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>00</month>
<year>2021</year>
</pub-date>
<volume>89</volume>
<numero>11</numero>
<fpage>884</fpage>
<lpage>890</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S0300-90412021001100006&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S0300-90412021001100006&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S0300-90412021001100006&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  ANTECEDENTES:  El carcinosarcoma de ovario, o tumor mixto de Müller, es una neoplasia infrecuente que representa alrededor del 1 al 4% de los carcinomas ováricos epiteliales. Su histología combina componentes sarcomatosos y carcinomatosos.  CASO CLÍNICO:  Paciente de 55 años, con diagnóstico de carcinosarcoma de ovario. Acudió a consulta debido a un sangrado uterino irregular y dolor abdominal. En la ecografía transvaginal se encontró una formación anexial sólida y heterogénea de 11.95 x 10.6 cm, con captación Doppler. El estudio se amplió con una tomografía axial computada (TAC) abdominopélvica y de tórax en la que se observó una tumoración en el lado izquierdo de 18 x 13 cm. Los marcadores tumorales se reportaron elevados: CEA 10.60, CA 125 91.3 y CA19.9 153 U/mL, con proteína HE-4 86.8 pmol/L, ligeramente disminuida. La laparotomía exploradora se completó con una cirugía para eliminar toda la carga tumoral. Se indicó quimioterapia con paclitaxel-carboplatino. El estudio histológico definitivo informó la existencia de una tumoración sólida-quística, compatible con un carcinosarcoma en el ovario izquierdo, con amplia diseminación peritoneal. A los 3 meses de la intervención, la paciente continuaba sin signos de recidiva.  CONCLUSIONES:  El carcinosarcoma es un tumor ginecológico poco frecuente pero muy agresivo; por su excepcional hallazgo aún no se dispone de criterios de tratamiento. Es decisivo fomentar investigaciones futuras acerca de los factores pronósticos y biomarcadores y desarrollar tratamientos dirigidos a las características moleculares de cada paciente.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  BACKGROUND:  Ovarian carcinosarcoma, or mixed Müllerian tumor, is a rare neoplasm that represents about 1 to 4% of epithelial ovarian carcinomas. Its histology combines sarcomatous and carcinomatous components.  CLINICAL CASE:  55-year-old female patient with a diagnosis of ovarian carcinosarcoma. She consulted due to irregular uterine bleeding and abdominal pain. Transvaginal ultrasound showed a solid and heterogeneous adnexal formation measuring 11.95 x 10.6 cm, with Doppler uptake. The study was expanded with an abdominopelvic and chest computed axial tomography (CT) scan in which a tumor was observed on the left side measuring 18 x 13 cm. Tumor markers were reported elevated: CEA 10.60, CA 125 91.3 and CA19.9 153 U/mL, with HE-4 protein 86.8 pmol/L, slightly decreased. Exploratory laparotomy was completed with R0 surgery. Chemotherapy with paclitaxel-carboplatin was indicated. The definitive histological study reported the existence of a solid-cystic tumor, compatible with a carcinosarcoma in the left ovary, with extensive peritoneal dissemination. Three months after surgery, the patient continued without signs of recurrence.  CONCLUSIONS:  Carcinosarcoma is a rare but very aggressive gynecologic tumor; because of its exceptional finding no treatment criteria are yet available. It is crucial to encourage future research on prognostic factors and biomarkers and to develop treatments targeted to the molecular characteristics of each patient.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Carcinosarcoma de ovario]]></kwd>
<kwd lng="es"><![CDATA[carcinoma epitelial de ovario]]></kwd>
<kwd lng="es"><![CDATA[sarcomatoso]]></kwd>
<kwd lng="es"><![CDATA[hemorragia uterina irregular]]></kwd>
<kwd lng="es"><![CDATA[dolor abdominal]]></kwd>
<kwd lng="es"><![CDATA[marcadores tumorales]]></kwd>
<kwd lng="es"><![CDATA[exploración]]></kwd>
<kwd lng="en"><![CDATA[Ovarian carcinosarcoma]]></kwd>
<kwd lng="en"><![CDATA[Epithelial ovarian carcinoma]]></kwd>
<kwd lng="en"><![CDATA[Sarcomatous]]></kwd>
<kwd lng="en"><![CDATA[Irregular uterine bleeding]]></kwd>
<kwd lng="en"><![CDATA[Abdominal pain]]></kwd>
<kwd lng="en"><![CDATA[Tumor markers]]></kwd>
<kwd lng="en"><![CDATA[Exploratory laparotomy]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[WP]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[YY]]></given-names>
</name>
<name>
<surname><![CDATA[Gao]]></surname>
<given-names><![CDATA[YT]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prognostic significance of lymph node metastasis and lymphadenectomy in early-stage ovarian carcinosarcoma]]></article-title>
<source><![CDATA[Cancer Manag Res]]></source>
<year>2018</year>
<volume>10</volume>
<page-range>1959-68</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhao]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Bellone]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Lopez]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Thakral]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition]]></article-title>
<source><![CDATA[Proc Natl Acad Sci U S A]]></source>
<year>2016</year>
<volume>113</volume>
<numero>43</numero>
<issue>43</issue>
<page-range>12238-43</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Guy]]></surname>
<given-names><![CDATA[JB]]></given-names>
</name>
<name>
<surname><![CDATA[Trone]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Castillo]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Forest]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Carcinosarcomas in female genital tracts general review]]></article-title>
<source><![CDATA[Bull Cancer]]></source>
<year>2014</year>
<volume>101</volume>
<numero>7-8</numero>
<issue>7-8</issue>
<page-range>760-4</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nizam]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Bustamante]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Shan]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Shih]]></surname>
<given-names><![CDATA[KK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Overall Survival and Adjuvant Therapy in Women with Ovarian Carcinosarcoma A Single-Institution Experience]]></article-title>
<source><![CDATA[Diagnostics (Basel)]]></source>
<year>2019</year>
<volume>9</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>200</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Montalvo-Esquivel]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Chanona-Vilchis]]></surname>
<given-names><![CDATA[JG]]></given-names>
</name>
<name>
<surname><![CDATA[Herrera-Gómez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Meneses-García]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Primary ovarian carcinosarcoma. Report of eight cases]]></article-title>
<source><![CDATA[Ginecol Obstet Mex]]></source>
<year>2014</year>
<volume>82</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>483-9</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Daimon]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Fujiwara]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Tanaka]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Tanaka]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A rare case of ovarian carcinosarcoma with squamous cell carcinoma]]></article-title>
<source><![CDATA[Ovarian Res]]></source>
<year>2019</year>
<volume>12</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>32</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhu]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
<name>
<surname><![CDATA[Feng]]></surname>
<given-names><![CDATA[YL]]></given-names>
</name>
<name>
<surname><![CDATA[Xu]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical analysis of 12 cases of ovarian carcinosarcoma]]></article-title>
<source><![CDATA[Nan Fang Yi Ke Da Xue Xue Bao]]></source>
<year>2011</year>
<volume>31</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>518-21</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[HJ]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[HM]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[MK]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[YK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prognostic assessment of sarcomatous histologic subtypes of ovarian carcinosarcoma]]></article-title>
<source><![CDATA[Obstet Gynecol Sci]]></source>
<year>2017</year>
<volume>60</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>350-6</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gotoh]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Sugiyama]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Takazawa]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Kato]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinically relevant molecular subtypes and genomic alteration-independent differentiation in gynecologic carcinosarcoma]]></article-title>
<source><![CDATA[Nat Commun]]></source>
<year>2019</year>
<volume>10</volume>
<page-range>4965</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rewsuwan]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Satabongkoch]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Suprasert]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Khunamornpong]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ovarian carcinosarcoma and its association with mature cystic teratoma and primary tubal carcinoma]]></article-title>
<source><![CDATA[Case Rep Pathol]]></source>
<year>2016</year>
<volume>2016</volume>
<page-range>2605045</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Han]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Altwerger]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Menderes]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Haines]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Novel targeted therapies in ovarian and uterine carcinosarcomas]]></article-title>
<source><![CDATA[Discov Med]]></source>
<year>2018</year>
<volume>25</volume>
<numero>140</numero>
<issue>140</issue>
<page-range>309-19</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kostov]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Kornovski]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Ivanova]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Dzhenkov]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ovarian carcinosarcoma with retroperitoneal para-aortic lymph node dissemination followed by an unusual postoperative complication a case report with a brief literature review]]></article-title>
<source><![CDATA[Diagnostics (Basel)]]></source>
<year>2020</year>
<volume>10</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1073</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pankaj]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Nazneen]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Kumari]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Kumari]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A rare tumor of the ovary carcinosarcoma report and review of literature]]></article-title>
<source><![CDATA[J Obstet Gynaecol India]]></source>
<year>2016</year>
<volume>66</volume>
<numero>Suppl 2</numero>
<issue>Suppl 2</issue>
<page-range>648-50</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Xu]]></surname>
<given-names><![CDATA[Q]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Zou]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Primitive ovarian carcinosarcoma a clinical and radiological analysis of five cases]]></article-title>
<source><![CDATA[J Ovarian Res]]></source>
<year>2020</year>
<volume>13</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>129</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Koirala]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Moon]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
<name>
<surname><![CDATA[Chuang]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical utility of preoperative assessment in ovarian cancer cytoreduction]]></article-title>
<source><![CDATA[Diagnostics (Basel)]]></source>
<year>2020</year>
<volume>10</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>568</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[García Prado]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[González Hernando]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Varillas Delgado]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Saiz Martínez]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diffusion-weighted magnetic resonance imaging in peritoneal carcinomatosis from suspected ovarian cancer diagnostic performance in correlation with surgical findings]]></article-title>
<source><![CDATA[Eur J Radiol]]></source>
<year>2019</year>
<volume>121</volume>
<page-range>108696</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Peres]]></surname>
<given-names><![CDATA[LC]]></given-names>
</name>
<name>
<surname><![CDATA[Cushing-Haugen]]></surname>
<given-names><![CDATA[KL]]></given-names>
</name>
<name>
<surname><![CDATA[Köbel]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Harris]]></surname>
<given-names><![CDATA[HR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Invasive epithelial ovarian cancer survival by histotype and disease stage]]></article-title>
<source><![CDATA[J Natl Cancer Inst]]></source>
<year>2019</year>
<volume>111</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>60-8</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[González Martín]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Oda]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Embleton]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
<name>
<surname><![CDATA[Pfisterer]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer]]></article-title>
<source><![CDATA[Gynecol Oncol]]></source>
<year>2019</year>
<volume>152</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>53-60</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Telli]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Timms]]></surname>
<given-names><![CDATA[KM]]></given-names>
</name>
<name>
<surname><![CDATA[Reid]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Hennessy]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Homologous Recombination Deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer]]></article-title>
<source><![CDATA[Clin Cancer Res]]></source>
<year>2016</year>
<volume>22</volume>
<numero>15</numero>
<issue>15</issue>
<page-range>3764-73</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[FW]]></given-names>
</name>
<name>
<surname><![CDATA[Tewari]]></surname>
<given-names><![CDATA[KS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[New targeted agents in gynecologic cancers synthetic lethality, homologous recombination deficiency, and PARP inhibitors]]></article-title>
<source><![CDATA[Curr Treat Options Oncol]]></source>
<year>2016</year>
<volume>17</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>12</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
